Пациенты старческого возраста с ИБС и хронической сердечной недостаточностью. Результаты применения симвастатина

The aim of the study was to investigate the possibility of the use of simvastatin at a daily dose of 20 mg in elderly patients with coronary artery disease and preserved left ventricular ejection fraction, complicated by CHF. Material and methods. 195 elderly patients (75 years and older) with CHD and CHF IIA-B phase, 2-3 functional class were involved in this study. The intervention group included 95 patients, the control group -100 patients. Patients in the intervention group was treated by simvastatin 20 mg/day. In the control group, lipid-lowering therapy was not performed. The endpoints of the study were the development of any acute vascular events or death from cardio-vascular diseases. Results. The relative risk of acute cardiovascular events and sudden deaths in the intervention group relative to the control group was 0,53 (CI 0,27-1,03, p= 0.05). Appointment of simvastatin in a daily dose of 20 mg significantly improved the lipid profile. Discussion: The study shows the effectiveness of clinical application of high doses of simvastatin in elderly patients with coronary artery disease complicated by heart failure